In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity
Women with advanced maternal age and morbid obesity, have a higher incidence of labor induction/ augmentation and cesarean section (CS), and are at a greater risk for postpartum hemorrhage (PPH). Oxytocin is the first line drug in the treatment of PPH, however, oxytocin receptor (OTR) desensitization has been recognized in the context of prolonged labors secondary to either endogenous or exogenous oxytocin exposure. It is unknown if oxytocin desensitization specifically affects contractility in women with advanced maternal age and morbid obesity when compared to younger or normal weight populations. Further it is not known if the higher incidence of PPH seen in these women is due to poor uterine contractility and/or poor response to oxytocin.
The investigators hypothesize that women with advanced maternal age and morbid obesity will exhibit poor myometrial contractility as compared to women that are younger and of normal body habitus, in both oxytocin pre-treated and untreated myometrium.
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G1X5
- Mount Sinai Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- patients who give written informed consent
- patients requiring elective primary or 1st repeat Cesarean section
- patients with gestational age 37-41 weeks
- non-labouring patients, not exposed to exogenous oxytocin
- Cesarean section under spinal anesthetic
- patients <30 years of age with a normal pre-pregnancy BMI (20 and 24.9 kg/m2)
- patients ≥40 years of age with a normal pre-pregnancy BMI
- patients with a BMI≥40 kg/m2 and age <30 years
Exclusion Criteria:
- patients who refuse to give written informed consent
- patients who require general anesthesia
- patients who have had more than one previous uterine surgery/CS
- patients with placental abnormalities (abruption, accreta, percreta)
- patients with bleeding disorders
- presence of any other risk factors for PPH
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
无干预:Control
A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
|
|
实验性的:Oxytocin
Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
|
催产素,10-10mol/L 至 10-5mol/L
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Motility index
大体时间:6-8 hours
|
6-8 hours
|
次要结果测量
结果测量 |
大体时间 |
---|---|
收缩幅度
大体时间:6-8小时
|
6-8小时
|
响应曲线下的综合面积 (AUC)
大体时间:6-8小时
|
6-8小时
|
收缩频率
大体时间:6-8小时
|
6-8小时
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
产后出血的临床试验
-
Wake Forest University Health Sciences主动,不招人